Meet the Team
-
Joshua Ismin
CHIEF EXECUTIVE OFFICER, COFOUNDER
-
Dr. Sam Banister
CHIEF SCIENTIFIC OFFICER, COFOUNDER
-
Dr. Will Jorgensen
DIRECTOR OF MEDICINAL CHEMISTRY
-
Dr. Joanna Hare
OPERATIONS MANAGER
-
Krista Licata
CHIEF OF STAFF
-
Dr. Jinlong Tan
COMPUTATIONAL CHEMIST
-
Dr. Lachlan Whish
MEDICINAL CHEMIST
-
Dr. Dilara Bahceci
HEAD OF COMMUNICATIONS
-
Dr. Nick Everett
PSYCHOPHARMACOLOGIST
-
Dr. Jianmin Duan
VICE PRESIDENT OF PHARMACOLOGY DMPK
-
Dr. Mario de la Fuente Revenga
SENIOR DIRECTOR, TRANSLATIONAL PHARMACOLOGY
-
Dr. Donald Gehlert
VICE PRESIDENT OF TRANSLATIONAL BIOLOGY
-
Kelly Burke
TALENT ACQUISITION PARTNER
Advisors
-
Ryan Bethencourt
STRATEGY ADVISOR
-
Anna Goldys
IP ADVISOR
-
Dr. Alan Kozikowski
DRUG DEVELOPMENT ADVISOR
-
Dr. John Krystal
-
Dr. Alex Kwan
SYSTEMS NEUROSCIENCE ADVISOR
-
Dr. Eric Nestler
NEUROSCIENCE ADVISOR
-
Graham Pechenik
IP ADVISOR
-
Ian Torrance
FINANCIAL ADVISOR
Partners
-
Psylo have taken up residency at UNSW’s Kensington campus to establish a cutting edge synthesis laboratory
-
Psylo has engaged CSIRO through its Kick-Start Program to evaluate the potential of Psylo’s novel compounds to induce neuroplasticity in vitro
-
Psylo is working with ANSTO’s National Deuteration Facility to explore deuteration on a number of Psylo's lead compounds
-
TIA voucher funding awarded to fund work with Monash University's Centre for Drug Candidate Optimisation (CDCO)
-
The National Institute on Drug Abuse, part of the National Institutes of Health, is testing Psylo’s novel compounds using the head-twitch response assay in rodents
-
Psylo is working with CCG’s computational platform to to build the In-Psylico virtual assay for multi-target optimisation
-
Psylo has implemented the CDD Vault informatics platform for managing all molecular SAR and screening assay data
Investors
